Editing 2C-T-2

{{Infobox drug
| Verifiedfields = verified
| Watchedfields = verified
| verifiedrevid = 477216630
| drug_name = 
| image = 2C-T-2 2DACS.svg
| width = 
| caption = 
| image2 = 2C-T-2 anim.gif
| width2 = 
| caption2 = 

<!-- Clinical data -->
| pronounce = 
| tradename = 
| Drugs.com = 
| MedlinePlus = 
| licence_CA = 
| licence_EU = 
| DailyMedID = 
| licence_US = 
| pregnancy_AU = 
| pregnancy_category = 
| dependency_liability = 
| addiction_liability = 
| routes_of_administration = [[Oral administration|Oral]]<ref name="Shulgin" />
| class = [[Serotonin]]; [[5-HT2 receptor|5-HT<sub>2</sub> receptor]] [[agonist]]; [[Serotonergic psychedelic]]; [[Hallucinogen]]
| ATC_prefix = None
| ATC_suffix = 

<!-- Legal status -->
| legal_AU = S9
| legal_BR = F2
| legal_CA = Schedule III
| legal_DE = 
| legal_US = Schedule I
| legal_status = 

<!-- Pharmacokinetic data -->
| bioavailability = 
| protein_bound = 
| metabolism = 
| metabolites = 
| onset = 
| elimination_half-life = 
| duration_of_action = 6–8 hours<ref name="Shulgin" />
| excretion = 

<!-- Identifiers -->
| CAS_number_Ref = {{cascite|correct|CAS}}
| CAS_number = 207740-24-7
| CAS_supplemental = 
| PubChem = 12074193
| PubChemSubstance = 
| IUPHAR_ligand = 
| DrugBank = 
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 16787961
| UNII = WPS2KSX2TJ
| KEGG = C22715
| ChEBI = 
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 339223
| NIAID_ChemDB = 
| PDB_ligand = 
| synonyms = 4-Ethylthio-2,5-dimethoxyphenethylamine; 2,5-Dimethoxy-4-ethylthiophenethylamine

<!-- Chemical data -->
| IUPAC_name = 2-[4-(ethylsulfanyl)-2,5-dimethoxyphenyl]ethan-1-amine
| C=12 | H=19 | N=1 | O=2 | S=1 
| SMILES = CCSc1cc(OC)c(cc1OC)CCN
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C12H19NO2S/c1-4-16-12-8-10(14-2)9(5-6-13)7-11(12)15-3/h7-8H,4-6,13H2,1-3H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = HCWQGDLBIKOJPM-UHFFFAOYSA-N
}}

'''2C-T-2''', also known as '''4-ethylthio-2,5-dimethoxyphenethylamine''', is a [[psychedelic drug|psychedelic]] and [[empathogen-entactogen|entactogenic]] [[phenethylamine]] of the [[2C (psychedelics)|2C family]].<ref>{{Cite web |date=2001-02-06 |title=Stolaroff's & Well's Study |url=https://erowid.org/chemicals/2ct7/article1/stolaroff.shtml |access-date=2023-10-30 |website=erowid.org}}</ref> It was first synthesized in 1981 by [[Alexander Shulgin]], and rated by him as one of the "magical half-dozen" most important psychedelic phenethylamine compounds.<ref name="Theobald">{{cite journal | vauthors = Theobald DS, Staack RF, Puetz M, Maurer HH | title = New designer drug 2,5-dimethoxy-4-ethylthio-beta-phenethylamine (2C-T-2): studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry | journal = Journal of Mass Spectrometry | volume = 40 | issue = 9 | pages = 1157–1172 | date = September 2005 | pmid = 16041763 | doi = 10.1002/jms.890 | bibcode = 2005JMSp...40.1157T }}</ref><ref name="Shulgin">{{cite web|url=http://www.erowid.org/library/books_online/pihkal/pihkal040.shtml|work = Erowid Online Books : "PIHKAL" | title = #40 2C-T-2 }}</ref>  The drug has structural and pharmacodynamic properties similar to those of [[2C-T-7]] ("Blue Mystic").

==Dosage==
In [[Alexander Shulgin]]'s book ''[[PiHKAL]]'', the dosage range is listed as 12 to 25&nbsp;mg.<ref name="Shulgin" />

==Pharmacology==
{| class="wikitable floatleft" style="font-size:small;"
|+ {{Nowrap|2C-T-2 activities}}
|-
! [[Biological target|Target]] !! [[Affinity (pharmacology)|Affinity]] (K<sub>i</sub>, nM)
|-
| [[5-HT1A receptor|5-HT<sub>1A</sub>]] || 370–1,740 (K<sub>i</sub>)<br />3,000 ({{Abbrlink|EC<sub>50</sub>|half-maximal effective concentration}})<br />76% ({{Abbrlink|E<sub>max</sub>|maximal efficacy}})
|-
| [[5-HT1B receptor|5-HT<sub>1B</sub>]] || 858
|-
| [[5-HT1D receptor|5-HT<sub>1D</sub>]] || 86
|-
| [[5-HT1E receptor|5-HT<sub>1E</sub>]] || 415
|-
| [[5-HT1F receptor|5-HT<sub>1F</sub>]] || {{Abbr|ND|No data}}
|-
| [[5-HT2A receptor|5-HT<sub>2A</sub>]] || 9–40 (K<sub>i</sub>)<br />0.354–80 ({{Abbr|EC<sub>50</sub>|half-maximal effective concentration}})<br />67–107% ({{Abbr|E<sub>max</sub>|maximal efficacy}})
|-
| [[5-HT2B receptor|5-HT<sub>2B</sub>]] || 6–69 (K<sub>i</sub>)<br />130 ({{Abbr|EC<sub>50</sub>|half-maximal effective concentration}})<br />75% ({{Abbr|E<sub>max</sub>|maximal efficacy}})
|-
| [[5-HT2C receptor|5-HT<sub>2C</sub>]] || 14–54 (K<sub>i</sub>)<br />0.0233–3.8 ({{Abbr|EC<sub>50</sub>|half-maximal effective concentration}})<br />87–107% ({{Abbr|E<sub>max</sub>|maximal efficacy}})
|-
| [[5-HT3 receptor|5-HT<sub>3</sub>]] || >10,000
|-
| [[5-HT4 receptor|5-HT<sub>4</sub>]] || {{Abbr|ND|No data}}
|-
| [[5-HT5A receptor|5-HT<sub>5A</sub>]] || >10,000
|-
| [[5-HT6 receptor|5-HT<sub>6</sub>]] || 1,362
|-
| [[5-HT7 receptor|5-HT<sub>7</sub>]] || 969
|-
| [[Alpha-1A adrenergic receptor|α<sub>1A</sub>]] || 17,000
|-
| [[Alpha-1B adrenergic receptor|α<sub>1B</sub>]] || >10,000
|-
| [[Alpha-1D adrenergic receptor|α<sub>1D</sub>]] || {{Abbr|ND|No data}}
|-
| [[Alpha-2A adrenergic receptor|α<sub>2A</sub>]] || 230–730
|-
| [[Alpha-2B adrenergic receptor|α<sub>2B</sub>]] || 982
|-
| [[Alpha-2C adrenergic receptor|α<sub>2C</sub>]] || 166
|-
| [[Beta-1 adrenergic receptor|β<sub>1</sub>]] || 9,202
|-
| [[Beta-2 adrenergic receptor|β<sub>2</sub>]] || 1,184
|-
| [[Beta-3 adrenergic receptor|β<sub>3</sub>]] || {{Abbr|ND|No data}}
|-
| [[D1 receptor|D<sub>1</sub>]] || 15,000
|-
| [[D2 receptor|D<sub>2</sub>]] || 2,795–5,100
|-
| [[D3 receptor|D<sub>3</sub>]] || 1,835–11,000
|-
| [[D4 receptor|D<sub>4</sub>]] || >10,000
|-
| [[D5 receptor|D<sub>5</sub>]] || >10,000
|-
| [[H1 receptor|H<sub>1</sub>]]–[[H4 receptor|H<sub>4</sub>]] || >10,000
|-
| [[Muscarinic acetylcholine M1 receptor|M<sub>1</sub>]] || >10,000
|-
| [[M2 receptor|M<sub>2</sub>]] || >10,000
|-
| [[Muscarinic acetylcholine M3 receptor|M<sub>3</sub>]] || 692
|-
| [[M4 receptor|M<sub>4</sub>]] || >10,000
|-
| [[M5 receptor|M<sub>5</sub>]] || 1,502
|-
| [[I1 receptor|I<sub>1</sub>]] || 2,080
|-
| [[Sigma-1 receptor|σ<sub>1</sub>]] || 3,870
|-
| [[Sigma-2 receptor|σ<sub>2</sub>]] || >10,000
|-
| {{Abbrlink|TAAR1|Trace amine-associated receptor 1}} || 2,200 (K<sub>i</sub>) (mouse)<br />40 (K<sub>i</sub>) (rat)<br />96 ({{Abbr|EC<sub>50</sub>|half-maximal effective concentration}}) (mouse)<br />4,300 ({{Abbr|EC<sub>50</sub>|half-maximal effective concentration}}) (rat)<br />>10,000 ({{Abbr|EC<sub>50</sub>|half-maximal effective concentration}}) (human)<br />54% ({{Abbr|E<sub>max</sub>|maximal efficacy}}) (mouse)<br />86% ({{Abbr|E<sub>max</sub>|maximal efficacy}}) (rat)
|-
| {{Abbrlink|SERT|Serotonin transporter}} || 13,000 (K<sub>i</sub>)<br />62,000 ({{Abbrlink|IC<sub>50</sub>|half-maximal inhibitory concentration}})<br />{{Abbr|IA|Inactive}} ({{Abbr|EC<sub>50</sub>|half-maximal effective concentration}})
|-
| {{Abbrlink|NET|Norepinephrine transporter}} || >30,000 (K<sub>i</sub>)<br />153,000 ({{Abbr|IC<sub>50</sub>|half-maximal inhibitory concentration}})<br />{{Abbr|IA|Inactive}} ({{Abbr|EC<sub>50</sub>|half-maximal effective concentration}})
|-
| {{Abbrlink|DAT|Dopamine transporter}} || >30,000 (K<sub>i</sub>)<br />332,000 ({{Abbr|IC<sub>50</sub>|half-maximal inhibitory concentration}})<br />{{Abbr|IA|Inactive}} ({{Abbr|EC<sub>50</sub>|half-maximal effective concentration}})
|-
| {{Abbrlink|MAO-A|Monoamine oxidase A}} || {{Abbr|ND|No data}} ({{Abbr|IC<sub>50</sub>|half-maximal inhibitory concentration}})
|-
| {{Abbrlink|MAO-B|Monoamine oxidase B}} || {{Abbr|ND|No data}} ({{Abbr|IC<sub>50</sub>|half-maximal inhibitory concentration}})
|- class="sortbottom"
| colspan="2" style="width: 1px; background-color:#eaecf0; text-align: center;" | '''Notes:''' The smaller the value, the more avidly the drug binds to the site. All proteins are human unless otherwise specified. '''Refs:''' <ref name="PDSPKiDatabase">{{cite web | title=Kᵢ Database | website=PDSP | date=16 March 2025 | url=https://pdsp.unc.edu/kidb2/kidb/web/kis-results/index?KisResultsSearch%5Binput_receptors%5D=&KisResultsSearch%5Binput_sources%5D=&KisResultsSearch%5Binput_species%5D=&KisResultsSearch%5Binput_hot_ligands%5D=&KisResultsSearch%5Binput_test_ligands%5D=&KisResultsSearch%5Binput_test_ligands%5D%5B%5D=12944&KisResultsSearch%5Binput_citations%5D=&KisResultsSearch%5BsearchType%5D=&KisResultsSearch%5Bki_val_from%5D=&KisResultsSearch%5Bki_val_to%5D=&KisResultsSearch%5Bcustom_ki_val%5D= | access-date=16 March 2025}}</ref><ref name="Ray2010">{{cite journal | vauthors = Ray TS | title = Psychedelics and the human receptorome | journal = PLOS ONE | volume = 5 | issue = 2 | pages = e9019 | date = February 2010 | pmid = 20126400 | pmc = 2814854 | doi = 10.1371/journal.pone.0009019 | doi-access = free | bibcode = 2010PLoSO...5.9019R | url = }}</ref><ref name="RickliLuethiReinisch2015">{{cite journal | vauthors = Rickli A, Luethi D, Reinisch J, Buchy D, Hoener MC, Liechti ME | title = Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs) | journal = Neuropharmacology | volume = 99 | issue = | pages = 546–553 | date = December 2015 | pmid = 26318099 | doi = 10.1016/j.neuropharm.2015.08.034 | url = https://psilosybiini.info/paperit/Receptor%20interaction%20profiles%20of%20novel%20N-2-methoxybenzyl%20(NBOMe)%20derivatives%20of%202,5-dimethoxy-substituted%20phenethylamines%20(2C%20drugs)%20(Rickli%20et%20al.,%202015).pdf}}</ref><ref name="EshlemanForsterWolfrum2014">{{cite journal | vauthors = Eshleman AJ, Forster MJ, Wolfrum KM, Johnson RA, Janowsky A, Gatch MB | title = Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function | journal = Psychopharmacology (Berl) | volume = 231 | issue = 5 | pages = 875–888 | date = March 2014 | pmid = 24142203 | pmc = 3945162 | doi = 10.1007/s00213-013-3303-6 | url = https://www.researchgate.net/profile/Michael-Forster-2/publication/258061356_Behavioral_and_neurochemical_pharmacology_of_six_psychoactive_substituted_phenethylamines_Mouse_locomotion_rat_drug_discrimination_and_in_vitro_receptor_and_transporter_binding_and_function/links/53d119a00cf2f7e53cfbcd68/Behavioral-and-neurochemical-pharmacology-of-six-psychoactive-substituted-phenethylamines-Mouse-locomotion-rat-drug-discrimination-and-in-vitro-receptor-and-transporter-binding-and-function.pdf}}</ref><ref name="PottieCannaertStove2020">{{cite journal | vauthors = Pottie E, Cannaert A, Stove CP | title = In vitro structure-activity relationship determination of 30 psychedelic new psychoactive substances by means of β-arrestin 2 recruitment to the serotonin 2A receptor | journal = Arch Toxicol | volume = 94 | issue = 10 | pages = 3449–3460 | date = October 2020 | pmid = 32627074 | doi = 10.1007/s00204-020-02836-w | bibcode = 2020ArTox..94.3449P | url = | hdl = 1854/LU-8687071 | hdl-access = free }}</ref><ref name="WagmannBrandtStratford2019">{{cite journal | vauthors = Wagmann L, Brandt SD, Stratford A, Maurer HH, Meyer MR | title = Interactions of phenethylamine-derived psychoactive substances of the 2C-series with human monoamine oxidases | journal = Drug Test Anal | volume = 11 | issue = 2 | pages = 318–324 | date = February 2019 | pmid = 30188017 | doi = 10.1002/dta.2494 | url = }}</ref><ref name="SimmlerBuchyChaboz2016">{{cite journal | vauthors = Simmler LD, Buchy D, Chaboz S, Hoener MC, Liechti ME | title = In Vitro Characterization of Psychoactive Substances at Rat, Mouse, and Human Trace Amine-Associated Receptor 1 | journal = J Pharmacol Exp Ther | volume = 357 | issue = 1 | pages = 134–144 | date = April 2016 | pmid = 26791601 | doi = 10.1124/jpet.115.229765 | url = https://web.archive.org/web/20250509235235/https://d1wqtxts1xzle7.cloudfront.net/74120533/eae6c6e62565b82d46b4d111bbea0f77b9c2-libre.pdf?1635931703=&response-content-disposition=inline%3B+filename%3DIn_Vitro_Characterization_of_Psychoactiv.pdf&Expires=1746838268&Signature=Sy4fJ90yUhxs68314NxYsW5PAaNrBGePRu35WRR4PIF-3YC7Z~sLdnCn5wfqqbLg9bDEGdt~oW55ugMP3D3jgA0BoRI~~GOb0NQOwrtfUEQK1PQs1uuN9qg5Y1ct8z5NsABm44RgtukkwRMdU6fO7OlfIsQ68hOiFk129Ll7UYqldxD2f1xhE2fTTfsxSpb8cMCJzHn7-ItqLdwnAUPFK7WggDIjmY1kCnaHLwIxMwdJCAq8L6DYzSTg7pZkbR8qlou~GXbTPQt~gYpyZTJp5hgW-7V6K5wLlQ7Z2xE7B0f9wEfuc1W1QNafg125Tr-vvAe4LEGKXV58bnn1bpfWKw__&Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA}}</ref>
|}

The [[mechanism of action]] that produces 2C-T-2’s [[Hallucinogen|hallucinogenic]] and [[Entheogen|entheogenic]] effects is shown to be most likely a result from action as a [[5-HT2A receptor|5-HT<sub>2A</sub>]], [[5-HT2B receptor|5-HT<sub>2B</sub>]], and [[5-HT2C receptor|5-HT<sub>2C</sub>]] [[5-HT receptor|serotonin receptor]] [[agonist]],<ref>{{cite journal | vauthors = Rickli A, Luethi D, Reinisch J, Buchy D, Hoener MC, Liechti ME | title = Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs) | journal = Neuropharmacology | volume = 99 | pages = 546–553 | date = December 2015 | pmid = 26318099 | doi = 10.1016/j.neuropharm.2015.08.034 | s2cid = 10382311 | url = http://edoc.unibas.ch/56163/1/20170921163006_59c3cceeb8e5d.pdf }}</ref> a mechanism of action shared by the hallucinogenic [[Substituted tryptamine|tryptamines]] and [[Substituted phenethylamine|phenethylamines]] to varying degrees.<ref>{{cite journal | vauthors = Eshleman AJ, Forster MJ, Wolfrum KM, Johnson RA, Janowsky A, Gatch MB | title = Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function | journal = Psychopharmacology | volume = 231 | issue = 5 | pages = 875–888 | date = March 2014 | pmid = 24142203 | pmc = 3945162 | doi = 10.1007/s00213-013-3303-6 }}</ref><ref>{{cite journal | vauthors = Rickli A, Moning OD, Hoener MC, Liechti ME | title = Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens | journal = European Neuropsychopharmacology | volume = 26 | issue = 8 | pages = 1327–1337 | date = August 2016 | pmid = 27216487 | doi = 10.1016/j.euroneuro.2016.05.001 | s2cid = 6685927 | url = http://edoc.unibas.ch/53326/1/20170117174852_587e4af45b658.pdf }}</ref> 2C-T-2 has also shown to be a partial agonist of [[Adrenergic receptor|adrenergic receptors]].<ref>{{cite journal | vauthors = Luethi D, Trachsel D, Hoener MC, Liechti ME | title = Monoamine receptor interaction profiles of 4-thio-substituted phenethylamines (2C-T drugs) | journal = Neuropharmacology | volume = 134 | issue = Pt A | pages = 141–148 | date = May 2018 | pmid = 28720478 | doi = 10.1016/j.neuropharm.2017.07.012 | series = Designer Drugs and Legal Highs | s2cid = 7135811 | url = https://edoc.unibas.ch/57358/1/20170920150712_59c2680084ec5.pdf }}</ref>

==Dangers==
A potential risk of [[neurotoxicity]] from 2C-T-2 use (and 2C chemical series in general) has been shown in serotonergic and [[Dopaminergic pathways|dopaminergic]] containing neurons. This has also been shown to be magnified in serotonergic-containing cells with combined use of 2C series drugs with alcohol, [[MDMA]], and [[methamphetamine]].<ref>{{Cite journal | vauthors = Asanuma M, Miyazaki I, Funada M |date= July 2020 |title=The neurotoxicity of psychoactive phenethylamines "2C series" in cultured monoaminergic neuronal cell lines |url=https://doi.org/10.1007/s11419-020-00527-w |journal=Forensic Toxicology |language=en |volume=38 |issue=2 |pages=394–408 |doi=10.1007/s11419-020-00527-w |s2cid= 211218167 |issn=1860-8973|url-access=subscription }}</ref>

Severe 'intoxication' on 2C series drugs has been observed as behavior that includes: intense [[Hallucination|hallucinations]], agitation, aggression, violence, [[dysphoria]], [[hypertension]], [[tachycardia]], [[Seizure|seizures]], and [[hyperthermia]].<ref>{{cite journal | vauthors = Dean BV, Stellpflug SJ, Burnett AM, Engebretsen KM | title = 2C or not 2C: phenethylamine designer drug review | journal = Journal of Medical Toxicology | volume = 9 | issue = 2 | pages = 172–178 | date = June 2013 | pmid = 23494844 | pmc = 3657019 | doi = 10.1007/s13181-013-0295-x }}</ref>

==Interactions==
{{See also|Psychedelic drug#Interactions|Trip killer#Serotonergic psychedelic antidotes}}

2C-T-2 is [[drug metabolism|metabolized]] by the [[monoamine oxidase]] (MAO) [[enzyme]]s [[MAO-A]] and [[MAO-B]].<ref name="DeanStellpflugBurnett2013">{{cite journal | vauthors = Dean BV, Stellpflug SJ, Burnett AM, Engebretsen KM | title = 2C or not 2C: phenethylamine designer drug review | journal = J Med Toxicol | volume = 9 | issue = 2 | pages = 172–178 | date = June 2013 | pmid = 23494844 | pmc = 3657019 | doi = 10.1007/s13181-013-0295-x | url = }}</ref><ref name="TheobaldMaurer2007">{{cite journal | vauthors = Theobald DS, Maurer HH | title = Identification of monoamine oxidase and cytochrome P450 isoenzymes involved in the deamination of phenethylamine-derived designer drugs (2C-series) | journal = Biochem Pharmacol | volume = 73 | issue = 2 | pages = 287–297 | date = January 2007 | pmid = 17067556 | doi = 10.1016/j.bcp.2006.09.022 | url = }}</ref> [[Monoamine oxidase inhibitor]]s (MAOIs) such as [[phenelzine]], [[tranylcypromine]], [[moclobemide]], and [[selegiline]] may potentiate the effects of 2C-T-2.<ref name="DeanStellpflugBurnett2013" /><ref name="TheobaldMaurer2007" /><ref name="HalmanKongSarris2024">{{Cite journal |vauthors=Halman A, Kong G, Sarris J, Perkins D |date=January 2024 |title=Drug-drug interactions involving classic psychedelics: A systematic review |journal=J Psychopharmacol |volume=38 |issue=1 |pages=3–18 |doi=10.1177/02698811231211219 |pmc=10851641 |pmid=37982394}}</ref> This may result in [[overdose]] and serious [[toxicity]].<ref name="HalmanKongSarris2024" /><ref name="DeanStellpflugBurnett2013" />

==Legal status==

===Argentina===
2C-T-2 is also a controlled substance in Argentina as well as [[2C-B]] and [[2C-I]].<ref>{{cite web | url = http://www.mpf.gov.ar/biblioteca/newsletter/n197/DECRETO_299_2010.pdf  | archive-url = https://web.archive.org/web/20110706084437/http://www.mpf.gov.ar/biblioteca/newsletter/n197/DECRETO_299_2010.pdf | archive-date = 6 July 2011 | title = DECRETO 299/2010 - PODER EJECUTIVO NACIONAL (P.E.N.) Estupefacientes - Actualización de la lista y demás sustancias químicas que deberán ser incluidas en los alcances de la ley 23.737 - Sustitución del anexo I del dec. 722/91. Publicado en: BOLETIN OFICIAL 04/03/2010 | trans-title = DECREE 299/2010 - NATIONAL EXECUTIVE POWER (P.E.N.) Narcotics - Updating of the list and other chemical substances that must be included in the scope of Law 23,737 - Substitution of annex I of dec. 722/91 | language = Spanish | date = 3 February 2010 }}</ref>

===Canada===
As of October 31, 2016, 2C-T-2 is a controlled substance (Schedule III) in Canada.<ref>{{cite web|url=http://gazette.gc.ca/rp-pr/p2/2016/2016-05-04/html/sor-dors72-eng.php|title=Canada Gazette – Regulations Amending the Food and Drug Regulations (Part J — 2C-phenethylamines)| publisher = Government of Canada, Public Works and Government Services Canada, Public Services and Procurement Canada, Integrated Services Branch, Canada |date=4 May 2016}}</ref>

===China===
As of October 2015 2C-T-2 is a controlled substance in China.<ref>{{cite web | url=http://www.sfda.gov.cn/WS01/CL0056/130753.html | title=关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | publisher=China Food and Drug Administration | date=27 September 2015 | language=zh | access-date=1 October 2015 | archive-url=https://web.archive.org/web/20151001222554/http://www.sfda.gov.cn/WS01/CL0056/130753.html | archive-date=1 October 2015 | url-status=dead }}</ref>

===Netherlands===
The Netherlands became the first country in the world to ban 2C-T-2, and classify it as a hard drug, by law. In April, 1999, 2C-T-2 became a list I drug of the [[Opium Law]].

===Sweden===
Schedule I in Sweden.

2C-T-2 was first classified as "health hazard" under the act [[:sv:Lagen om förbud mot vissa hälsofarliga varor|''Lagen om förbud mot vissa hälsofarliga varor'']] (translated ''Act on the Prohibition of Certain Goods Dangerous to Health'') as of April 1, 1999, under SFS 1999:58<ref>{{cite web|url=http://www.notisum.se/rnp/sls/fakta/a9990058.HTM|title=Förordning (1999:58) om förbud mot vissa hälsofarliga varor|website=www.notisum.se|access-date=2013-09-15|archive-date=2013-10-04|archive-url=https://web.archive.org/web/20131004215233/http://www.notisum.se/rnp/sls/fakta/a9990058.HTM|url-status=dead}}</ref> that made it illegal to sell or possess.

[[Riksdag|The Riksdag]] added 2C-T-2 to [[:sv:Narkotikastrafflagen|Narcotic Drugs Punishments Act]] under ''Swedish schedule I'' (''"substances, plant materials and fungi which normally do not have medical use"'') as of March 16, 2004, published by [[Medical Products Agency (Sweden)|Medical Products Agency (MPA)]] in regulation ''LVFS 2004:3'' listed as 2C-T-2, 2,5-dimetoxi-4-etyltiofenetylamin.<ref>{{cite web | url = https://lakemedelsverket.se/upload/lvfs/LVFS_2004-3.pdf | title = Läkemedelsverkets författningssamling | publisher = lakemedelsverket.se | language = sv}}</ref>

===United Kingdom===
2C-T-2 and all other compounds featured in [[PiHKAL]] are illegal drugs in the [[United Kingdom]].

===United States===
2C-T-2 is specifically listed as a schedule I substance under SEC. 1152 of S.3187: [[Food and Drug Administration Safety and Innovation Act of 2012]].<ref>{{Cite web |title=21 U.S. Code § 812 - Schedules of controlled substances |url=https://www.law.cornell.edu/uscode/text/21/812|access-date=2022-12-22 |website=[[Cornell University]] |language=en}}</ref>

===Australia===
2C-T-2 is considered a Schedule 9 prohibited substance in Australia under the [[Standard for the Uniform Scheduling of Medicines and Poisons|Poisons Standard]] (October 2015).<ref name="Poisons Standard">{{cite web | title = Poisons Standard October 2015 | url = https://www.comlaw.gov.au/Details/F2015L01534 | date = October 2015 | work = Federal Register of Legislation | publisher = Australian Government, Department of Health, Therapeutic Goods Administration }}</ref> A Schedule 9 substance is a substance which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities.<ref name="Poisons Standard" />

==See also==
* [[2C-T]]
* [[2C-T-4]]
* [[2C-T-7]]
* [[Aleph-2]]

== References ==
{{reflist}}

== External links ==
* [https://isomerdesign.com/pihkal/explore/40 2C-T-2 - Isomer Design]
* [https://psychonautwiki.org/wiki/2C-T-2 2C-T-2 - PsychonautWiki]
* [http://www.erowid.org/chemicals/2ct2/2ct2.shtml 2C-T-2 vault - Erowid]
* [https://erowid.org/library/books_online/pihkal/pihkal040.shtml 2C-T-2 - PiHKAL - Erowid]
* [https://isomerdesign.com/pihkal/read/pk/40 2C-T-2 - PiHKAL - Isomer Design]
* [https://tripsitter.com/2ct2/ 2C-T-2: Potential Therapeutic Alternative to MDMA?]
* [http://www.erowid.org/chemicals/2ct7/article1/article1.shtml Sulfurous Samadhi: An Investigation of 2C-T-2 & 2C-T-7 - Erowid]

{{Psychedelics}}
{{Serotonin receptor modulators}}
{{TAAR modulators}}
{{Phenethylamines}}

[[Category:2C (psychedelics)]]
[[Category:5-HT2A agonists]]
[[Category:5-HT2B agonists]]
[[Category:5-HT2C agonists]]
[[Category:Alexander Shulgin]]
[[Category:Designer drugs]]
[[Category:O-methylated phenols]]
[[Category:Psychedelic phenethylamines]]
[[Category:Substances discovered in the 1980s]]
[[Category:TAAR1 modulators]]
[[Category:Thioethers]]